Clinical Utility of Various Formulations of Calcipotriene and Betamethasone Dipropionate for the Treatment of Plaque Psoriasis in Patients Aged 12 Years or Older
Kamila Kędra,1,2 Adam Reich1 1Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszów, 35-055, Poland; 2Doctoral School, University of Rzeszow, Rzeszow, PolandCorrespondence: Adam Reich, Email adamandrzejreich@gmail.comAbstract: Plaque-type...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2024-12-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/clinical-utility-of-various-formulations-of-calcipotriene-andbetametha-peer-reviewed-fulltext-article-DDDT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850169126212861952 |
|---|---|
| author | Kędra K Reich A |
| author_facet | Kędra K Reich A |
| author_sort | Kędra K |
| collection | DOAJ |
| description | Kamila Kędra,1,2 Adam Reich1 1Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszów, 35-055, Poland; 2Doctoral School, University of Rzeszow, Rzeszow, PolandCorrespondence: Adam Reich, Email adamandrzejreich@gmail.comAbstract: Plaque-type psoriasis is a chronic immune-mediated inflammatory skin disease of uncertain etiology, significantly impacting patient well-being. This chronic condition not only contributes to stigmatization and mental health challenges but also poses an independent risk for cardiovascular and other comorbid diseases. Affecting approximately 60 million people globally, psoriasis manifests primarily as mild-to-moderate disease in about 80% of cases, where topical therapy is pivotal. The most commonly used topical antipsoriatic therapy involves a combination of vitamin D3 analog (calcipotriene – Cal) and a synthetic potent corticosteroid (betamethasone dipropionate – BD). Various formulations of Cal/BD, including ointment, gel (topical suspension), and aerosol foam, have been approved by the US Food and Drug Administration (FDA). The cream based on the PAD (Polyaphron Dispersion) technology is another formulation of this combination drug, expanding the therapeutic options for patients with psoriasis. This article summarizes the most relevant published studies concerning the efficacy and safety of different calcipotriol and betamethasone formulations treating of plaque-type psoriasis in patients aged 12 or older.Keywords: psoriasis vulgaris, calcipotriene, betamethasone dipropionate, topical therapy, vitamin D derivatives, corticosteroids |
| format | Article |
| id | doaj-art-82a8ea8cf70e463db32e6028b56bd6fb |
| institution | OA Journals |
| issn | 1177-8881 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj-art-82a8ea8cf70e463db32e6028b56bd6fb2025-08-20T02:20:48ZengDove Medical PressDrug Design, Development and Therapy1177-88812024-12-01Volume 185827583998109Clinical Utility of Various Formulations of Calcipotriene and Betamethasone Dipropionate for the Treatment of Plaque Psoriasis in Patients Aged 12 Years or OlderKędra KReich AKamila Kędra,1,2 Adam Reich1 1Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszów, 35-055, Poland; 2Doctoral School, University of Rzeszow, Rzeszow, PolandCorrespondence: Adam Reich, Email adamandrzejreich@gmail.comAbstract: Plaque-type psoriasis is a chronic immune-mediated inflammatory skin disease of uncertain etiology, significantly impacting patient well-being. This chronic condition not only contributes to stigmatization and mental health challenges but also poses an independent risk for cardiovascular and other comorbid diseases. Affecting approximately 60 million people globally, psoriasis manifests primarily as mild-to-moderate disease in about 80% of cases, where topical therapy is pivotal. The most commonly used topical antipsoriatic therapy involves a combination of vitamin D3 analog (calcipotriene – Cal) and a synthetic potent corticosteroid (betamethasone dipropionate – BD). Various formulations of Cal/BD, including ointment, gel (topical suspension), and aerosol foam, have been approved by the US Food and Drug Administration (FDA). The cream based on the PAD (Polyaphron Dispersion) technology is another formulation of this combination drug, expanding the therapeutic options for patients with psoriasis. This article summarizes the most relevant published studies concerning the efficacy and safety of different calcipotriol and betamethasone formulations treating of plaque-type psoriasis in patients aged 12 or older.Keywords: psoriasis vulgaris, calcipotriene, betamethasone dipropionate, topical therapy, vitamin D derivatives, corticosteroidshttps://www.dovepress.com/clinical-utility-of-various-formulations-of-calcipotriene-andbetametha-peer-reviewed-fulltext-article-DDDTpsoriasis vulgariscalcipotrienebetamethasone dipropionatetopical therapyvitamin d derivativescorticosteroids |
| spellingShingle | Kędra K Reich A Clinical Utility of Various Formulations of Calcipotriene and Betamethasone Dipropionate for the Treatment of Plaque Psoriasis in Patients Aged 12 Years or Older Drug Design, Development and Therapy psoriasis vulgaris calcipotriene betamethasone dipropionate topical therapy vitamin d derivatives corticosteroids |
| title | Clinical Utility of Various Formulations of Calcipotriene and Betamethasone Dipropionate for the Treatment of Plaque Psoriasis in Patients Aged 12 Years or Older |
| title_full | Clinical Utility of Various Formulations of Calcipotriene and Betamethasone Dipropionate for the Treatment of Plaque Psoriasis in Patients Aged 12 Years or Older |
| title_fullStr | Clinical Utility of Various Formulations of Calcipotriene and Betamethasone Dipropionate for the Treatment of Plaque Psoriasis in Patients Aged 12 Years or Older |
| title_full_unstemmed | Clinical Utility of Various Formulations of Calcipotriene and Betamethasone Dipropionate for the Treatment of Plaque Psoriasis in Patients Aged 12 Years or Older |
| title_short | Clinical Utility of Various Formulations of Calcipotriene and Betamethasone Dipropionate for the Treatment of Plaque Psoriasis in Patients Aged 12 Years or Older |
| title_sort | clinical utility of various formulations of calcipotriene and nbsp betamethasone nbsp dipropionate for the treatment of plaque psoriasis in patients aged 12 years or older |
| topic | psoriasis vulgaris calcipotriene betamethasone dipropionate topical therapy vitamin d derivatives corticosteroids |
| url | https://www.dovepress.com/clinical-utility-of-various-formulations-of-calcipotriene-andbetametha-peer-reviewed-fulltext-article-DDDT |
| work_keys_str_mv | AT kedrak clinicalutilityofvariousformulationsofcalcipotrieneandnbspbetamethasonenbspdipropionateforthetreatmentofplaquepsoriasisinpatientsaged12yearsorolder AT reicha clinicalutilityofvariousformulationsofcalcipotrieneandnbspbetamethasonenbspdipropionateforthetreatmentofplaquepsoriasisinpatientsaged12yearsorolder |